2nd GLP-1-Based Therapeutics Summit 2025 Hyatt Regency Boston, Boston
It is no secret that GLP-1 receptor agonists have transformed the treatment of obesity and diabetes. The past 12 months have seen the GLP-1 landscape transform into something truly unrecognizable in previous years, with the global GLP-1 analogues market valued at US$47.4 billion in 2024.
With the next frontier of these blockbuster therapeutics well on its way to approval, the GLP-1 field is only going to grow, with novel combinations, indications, and formulations being explored. From MASH to Parkinson’s disease, there is potential for GLP-1s to become a ‘magic bullet’ across healthcare, only adding to the ever-increasing market value.
In this highly competitive market, Novo Nordisk and Eli Lilly currently lead with first-in-class GLP-1 therapies. However, the race is now focused on developing ‘best-in-class’ therapies that offer superior efficacy, particularly in weight loss, and are delivered through more convenient formats.
⌛ Event Dates & Venue
👨👧👦 Social Networks
💸 Website & Tickets
Go to Event Website Drug Developer Pricing* - Conference + 2 Workshops : USD 4197.00, Drug Developer Pricing* - Conference + 1 Workshop: USD 3598.00, Drug Developer Pricing* - Conference Only: USD 2999.00, Academic Pricing** - Conference + 2 Workshops: USD 3597.00, Academic Pricing** - Conference + 1 Workshop Only: USD 3098.00, Academic Pricing** - Conference Only: USD 2599.00, Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00, Solution Provider Pricing - Conference + 1 Workshop: USD 4398.00, Solution Provider Pricing - Conference Only: USD 3699.00
Advertisements